Chest
Clinical InvestigationsLUNG CANCERGrading of Tumor Regression in Non-small Cell Lung Cancer: Morphology and Prognosis
Section snippets
Eligibility Criteria
The study was approved by the ethical committee of the University of Mu¨nster, Germany.
From April 1992 to September 1995, patients with NSCLC stage IIIA (tumor stage T1–3N2M0) with histologically confirmed N2 status or stage IIIB (tumor stage T4N1–3M0/T1–4N3M0) were enrolled in the study. Patients with involvement of the supraclavicular lymph nodes or who had positive test results for pleural effusion were not eligible. Further requirements were a favorable medical condition (Eastern
Results
From April 1992 to September 1995, 54 patients (5 women and 49 men) with a median age of 57 years (age range, 37 to 69 years) were enrolled in the study. Twenty-five patients had stage IIIA disease, and 29 patients had stage IIIB disease. Histology identified 36 tumors as squamous cell carcinomas and 18 tumors as adenocarcinomas (Table 1). In 40 patients in the study population, surgery was performed after the completion of induction therapy. Of the remaining 14 patients, 3 were technically
Discussion
In a phase II study, 54 patients with locally advanced NSCLC (stages IIIA and IIIB) were treated with neoadjuvant chemotherapy followed by radiochemotherapy. In 40 of these patients, surgery was performed.10 Comparing the population analyzed here with 50 patients with previously untreated NSCLCs, we were able to show that spontaneous and therapy-induced tumor regression can be distinguished with high certainty.5 Several morphologic changes that were due to neoadjuvant chemoradiotherapy were
Acknowledgment
The authors thank Professor W. Bo¨cker (Mu¨nster, Germany), Professor K.-F. Bu¨rrig (Hildesheim, Germany), Dr. W.-P. Kunze (Hemer, Germany), and Professor W. Lang (Hannover, Germany) for their kind support in contributing biopsy and resection specimens to this study, and Dr. A. Heinecke (Mu¨nster, Germany) for his support in statistical analysis. This article is dedicated to Professor Dr. K.-M. Mu¨ller (Bochum, Germany) on the occasion of his 60th birthday.
References (23)
Revisions in the international system for staging lung cancer
Chest
(1997)- et al.
Combined radiotherapy and resection for carcinoma of the bronchus
Lancet
(1955) - et al.
Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma
J Thorac Cardiovasc Surg
(1970) - et al.
Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer
Ann Thorac Surg
(1989) - et al.
Combined modality treatment for locally advanced non-small cell lung cancer
- et al.
Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer
J Clin Oncol
(1997) - et al.
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805
J Clin Oncol
(1995) - et al.
Tumour regression in non-small cell lung cancer following neoadjuvant therapy: histological assessment
J Cancer Res Clin Oncol
(1997) - et al.
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
West New Drugs
(1992) - et al.
Non-parametrics. estimation from incomplete observations
J Am Stat Assoc
(1958)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
Br J Cancer
Cited by (149)
Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway
2024, Biomedicine and PharmacotherapyPathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy
2024, Modern PathologyPathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer
2023, Surgical Pathology Clinics
This research was supported by the North Rhine Westfalian Cancer Society, Du¨sseldorf, Germany.